Comparison of Effect of Antidepressants on Psychomotor Functions

Overview

Journal Indian J Psychol Med

Publisher Sage Publications

Specialty Psychiatry

Date 2017 Mar 3

PMID 28250562

Citations 1

Authors

Pranjali P Mendhe

Samidh P Shah

Mira K Desai

Minakshi N Parikh

Affiliations

Soon will be listed here.

Abstract

Objective: The comparison of the effect of antidepressants on psychomotor functions in patients with endogenous depression.

Materials And Methods: This prospective interventional study was carried out at a tertiary care teaching hospital on 95 literate patients with newly diagnosed endogenous depression matching inclusion and exclusion criteria. Patients were prescribed either desvenlafaxine (50 mg) or fluoxetine (40 mg) or sertraline (50 mg). Psychomotor functions were assessed by digit letter substitution, six letter cancellation, choice reaction time, hand steadiness and flicker fusion test at the baseline 1 month and 3 month. Efficacy of drugs was also measured by Hamilton rating scale for depression. Data were analyzed by using ANOVA and < 0.05 was considered as statistically significant.

Results: A total of 95 patients were enrolled. Fluoxetine, desvenlafaxine, and sertraline were prescribed in 32, 32, and 31 patients, respectively. At the end of 3 months, a significant improvement in psychomotor functions was observed in patients treated with sertraline ( < 0.05), while desvenlafaxine-treated patients did not show any significant change in any of the tests. Surprisingly, fluoxetine-treated patients showed deterioration in all psychomotor tests ( < 0.05). Hamilton rating score improved at the end of 3 months treatment as compared to baseline. Most commonly observed adverse reactions in all three drug groups were nausea ( = 20), dizziness ( = 3), headache ( = 20), and diarrhea ( = 3).

Conclusion: Sertraline significantly improves psychomotor function as compared to desvenlafaxine while fluoxetine impairs.

Citing Articles

Non-REM sleep in major depressive disorder.

Bovy L, Weber F, Tendolkar I, Fernandez G, Czisch M, Steiger A Neuroimage Clin. 2022; 36:103275.

PMID: 36451376 PMC: 9723407. DOI: 10.1016/j.nicl.2022.103275.

References

Lustman P, Freedland K, Griffith L, Clouse R . Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care. 2000; 23(5):618-23. DOI: 10.2337/diacare.23.5.618. View

Lyketsos C, Sheppard J, Steele C, Kopunek S, Steinberg M, Baker A . Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: initial results from the Depression in Alzheimer's Disease study. Am J Psychiatry. 2000; 157(10):1686-9. DOI: 10.1176/appi.ajp.157.10.1686. View

Hamilton M . A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960; 23:56-62. PMC: 495331. DOI: 10.1136/jnnp.23.1.56. View

Rabkin J, Wagner G, McElhiney M, Rabkin R, Lin S . Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J Clin Psychopharmacol. 2004; 24(4):379-85. DOI: 10.1097/01.jcp.0000132442.35478.3c. View

Hindmarch I, Kerr J . Behavioural toxicity of antidepressants with particular reference to moclobemide. Psychopharmacology (Berl). 1992; 106 Suppl:S49-55. DOI: 10.1007/BF02246236. View

Van der Elst W, van Boxtel M, van Breukelen G, Jolles J . The Letter Digit Substitution Test: normative data for 1,858 healthy participants aged 24-81 from the Maastricht Aging Study (MAAS): influence of age, education, and sex. J Clin Exp Neuropsychol. 2006; 28(6):998-1009. DOI: 10.1080/13803390591004428. View

Plenge P, Mellerup E, Laursen H . Affinity modulation of [3H]imipramine, [3H]paroxetine and [3H]citalopram binding to the 5-HT transporter from brain and platelets. Eur J Pharmacol. 1991; 206(3):243-50. DOI: 10.1016/s0922-4106(05)80025-2. View

Tourian K, Padmanabhan S, Groark J, Brisard C, Farrington D . Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. Clin Ther. 2009; 31 Pt 1:1405-23. DOI: 10.1016/j.clinthera.2009.07.006. View

Lawlor B, Newhouse P, Balkin T, Molchan S, Mellow A, Murphy D . A preliminary study of the effects of nighttime administration of the serotonin agonist, m-CPP, on sleep architecture and behavior in healthy volunteers. Biol Psychiatry. 1991; 29(3):281-6. DOI: 10.1016/0006-3223(91)91290-8. View

10.

Soares C, Fayyad R, Guico-Pabia C . Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder. J Clin Psychopharmacol. 2013; 34(1):57-65. DOI: 10.1097/JCP.0000000000000049. View

11.

Sherwood N . Comparative behavioural toxicity of the selective serotonin reuptake inhibitors. Hum Psychopharmacol. 2018; 10 Suppl 3(S3):S159-S162. DOI: 10.1002/hup.470100904. View

12.

Nicholson A, Pascoe P . Studies on the modulation of the sleep-wakefulness continuum in man by fluoxetine, a 5-HT uptake inhibitor. Neuropharmacology. 1988; 27(6):597-602. DOI: 10.1016/0028-3908(88)90180-3. View

13.

Turner P . Critical flicker frequency and centrally-acting drugs. Br J Ophthalmol. 1968; 52(3):245-50. PMC: 506563. DOI: 10.1136/bjo.52.3.245. View

14.

Stone B . Pencil and paper tests--sensitivity to psychotropic drugs. Br J Clin Pharmacol. 1984; 18 Suppl 1:15S-20S. PMC: 1463334. DOI: 10.1111/j.1365-2125.1984.tb02578.x. View

15.

Hindmarch I . Psychomotor function and psychoactive drugs. Br J Clin Pharmacol. 1980; 10(3):189-209. PMC: 1430071. DOI: 10.1111/j.1365-2125.1980.tb01745.x. View

16.

Kerr J, Powell J, Hindmarch I . The effects of reboxetine and amitriptyline, with and without alcohol on cognitive function and psychomotor performance. Br J Clin Pharmacol. 1996; 42(2):239-41. PMC: 2042654. DOI: 10.1046/j.1365-2125.1996.39016.x. View

17.

Ramaekers J, Ansseau M, Muntjewerff N, Sweens J, OHanlon J . Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients. Int Clin Psychopharmacol. 1997; 12(3):159-69. DOI: 10.1097/00004850-199705000-00007. View